🦘Cacatman's Personal Coronavirus COVID-19 Update Thread

[cacatman]

Prevention - Colchicine reduces risk of COVID-19 complications
Colchicine has reduced by 21% the risk of death or hospitalizations in patients with COVID-19 compared to placebo. This result obtained for the global study population of 4488 patients approached statistical significance. The analysis of the 4159 patients in whom the diagnosis of COVID-19 was proven by a naso-pharyngeal PCR test has shown that the use of colchicine was associated with statistically significant reductions in the risk of death or hospitalization compared to placebo. In these patients with a proven diagnosis of COVID-19, colchicine reduced hospitalizations by 25%, the need for mechanical ventilation by 50%, and deaths by 44%. This major scientific discovery makes colchicine the world’s first oral drug that could be used to treat non-hospitalized patients with COVID-19.

COVID - 19 - Clinical Trial | ColCorona

On January 22, 2021, the Montreal Heart Institute announced positive results from COLCORONA trial.The COLCORONA study manuscript is now available in the public domain.

www.colcorona.net

The addition of colchicine to standard treatment reduces the duration of supplemental oxygen therapy and time to hospital discharge among patients with moderate-to-severe COVID-19, suggest findings from a randomized controlled trial.

Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial | RMD Open

In the RECOVERY trial, not shown to have a benefit. In adults hospitalised with COVID-19, colchicine was not associated with reductions in 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death.

Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

In adults hospitalised with COVID-19, colchicine was not associated with reductions in 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death.

www.thelancet.com

 

[cacatman]

Vaccine Information FAQs for Rollout in the USA

Answers to All Your Questions About Getting Vaccinated for Covid-19 (Published 2023)

Times reporters answered questions from readers about getting the vaccine, what to expect and what happens next.

www.nytimes.com

 

[cacatman]

Variants of COVID-19 is a Concern
New variants of SARS-CoV-2 are making headlines and, for some, raising concerns. The biggest worry lies in whether the changes in the genome of the virus will affect the efficacy of the vaccine. Now, new research from the University of Pittsburgh School of Medicine suggests that SARS-CoV-2 can evade immune responses, in a recurring pattern of evolution, by selectively deleting small bits of its genetic sequence.

AAAS

science.sciencemag.org

 

[cacatman]

General Information About COVID-19 from Harvard Medical School

Coronavirus Resource Center - Harvard Health

COVID-19 (coronavirus disease 2019) is a respiratory illness caused by the SARS-CoV-2 virus. It is very contagious, and spreads quickly. Most people with COVID-19 have mild respiratory symptoms that feel much like a cold or flu. But it can be much more serious for older adults, people with...

www.health.harvard.edu

 

[cacatman]

Using Computers, University of Copenhagen Can Predict Respirator/Death in COVID-19 Patients
Using patient data, artificial intelligence can make a 90 percent accurate assessment of whether a person will die from COVID-19 or not, according to new research at the University of Copenhagen. Body mass index (BMI), gender and high blood pressure are among the most heavily weighted factors. The research can be used to predict the number of patients in hospitals, who will need a respirator and determine who ought to be first in line for a vaccination.

“Our results demonstrate, unsurprisingly, that age and BMI are the most decisive parameters for how severely a person will be affected by COVID-19. But the likelihood of dying or ending up on a respirator is also heightened if you are male, have high blood pressure or a neurological disease,” explains Mads Nielsen.

The diseases and health factors that, according to the study, have the most influence on whether a patient ends up on a respirator after being infected with COVID-19 are in order of priority: BMI, age, high blood pressure, being male, neurological diseases, COPD, asthma, diabetes and heart disease.

Developing and validating COVID-19 adverse outcome risk prediction models from a bi-national European cohort of 5594 patients - Scientific Reports

Patients with severe COVID-19 have overwhelmed healthcare systems worldwide. We hypothesized that machine learning (ML) models could be used to predict risks at different stages of management and thereby provide insights into drivers and prognostic markers of disease progression and death. From...

www.nature.com

Computer can determine whether you’ll die from COVID

Using patient data, artificial intelligence can make a 90 percent accurate assessment of whether a person will die from COVID-19 or not, according to new research at the University of Copenhagen. Body mass index (BMI), gender and high blood pressure are among the most heavily weighted factors...

www.science.ku.dk

 

[cacatman]

Treatment - Bevacizumab may be helpful in Severe COVID-19
The anti-cancer therapy bevacizumab may hasten recovery and reduce the rate of mortality in people with the coronavirus disease 2019 (COVID-19).

Efficacy and tolerability of bevacizumab in patients with severe Covid-19 - Nature Communications

In this single-arm clinical trial, the authors show that treatment of COVID-19 patients with bevacizumab, an anti-vascular endothelial growth factor drug, can improve PaO2/FiO2 ratios and oxygen-support status. Relative to an external control group, bevacizumab shows clinical efficacy by...

www.nature.com

 

[cacatman]

Sinopharm Vaccine
86% efficacy, no severe/moderate infections

Sinopharm vaccine explainer: Everything you need to know after UAE approval

The United Arab Emirates has officially registered China’s Sinopharm COVID-19 vaccine, potentially paving the way for mass vaccinations for the general

english.alarabiya.net

 

[cacatman]

Maturation and persistence of the anti-SARS-CoV-2 memory B cell response​

Memory B cells play a fundamental role in host defenses against viruses, but to date, their role has been relatively unsettled in the context of SARS-CoV-2. We report here a longitudinal single-cell and repertoire profiling of the B cell response up to 6 months in mild and severe COVID-19 patients. Distinct SARS-CoV-2 spike-specific activated B cell clones fueled an early antibody-secreting cell burst as well as a durable synchronous germinal center response. While highly mutated memory B cells, including pre-existing cross-reactive seasonal Betacoronavirus-specific clones, were recruited early in the response, neutralizing SARS-CoV-2 RBD-specific clones accumulated with time and largely contributed to the late, remarkably stable, memory B cell pool. Highlighting germinal center maturation, these cells displayed clear accumulation of somatic mutations in their variable region genes over time. Overall, these findings demonstrate that an antigen-driven activation persisted and matured up to 6 months after SARS-CoV-2 infection and may provide long-term protection.

Maturation and persistence of the anti-SARS-CoV-2 memory B cell response

The B cell response against SARS-CoV-2 shows a temporal shift from an extrafollicular reaction that includes memory B cells against seasonal coronaviruses toward a germinal center-dependent memory response encoding (spike-specific) neutralizing antibodies.

www.cell.com

 

[cacatman]

Zinc & Vitamin C Not Found to be Helpful in Reducing Length of Symptoms
In this randomized clinical trial of 214 patients with confirmed SARS-CoV-2 infection receiving outpatient care, there was no significant difference in the duration of symptoms among the 4 groups.

Effect of Zinc and Ascorbic Acid on Symptom Length Among Patients With SARS-CoV-2

This randomized clinical trial examines whether high-dose zinc and/or high-dose ascorbic acid reduces the severity or duration of symptoms compared with usual care among ambulatory patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

jamanetwork.com

 

[cacatman]

Serology Tests for COVID-19 That are Approved in the USA

complete list of Blood tests.

Name of Test	Manufacturer	Type of test	Sensitivity	Specificity
VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total Reagent Pack	Ortho Clinical Diagnostics	ChLIA	80% (0-8 days), 100% (8+ days)	100%
UBI SARS-CoV-2 ELISA	United Biomedical, Inc.	ELISA	38.5% (0-7 days), 79.5% (7-14 days), 100% (15+ days)	100.00%
EliA SARS-CoV-2-Sp1 IgG Test	Phadia AB	Fluoroenzyme Immunoassay	15.4% (0-7 days), 58.2% (7-14 days), 97.6% (15+ days)	99.40%
RapCov Rapid COVID-19 Test	ADVAITE, Inc.	RST	90.00%	95.20%
Dimension EXL SARS‑CoV‑2 IgG (CV2G)	Siemens Healthcare Diagnostics Inc.	ChLIA	61.1% (0-7 days), 92.9% (7-14 days), 100% (15+ days)	100.00%
Dimension Vista SARS‑CoV‑2 IgG (COV2G)	Siemens Healthcare Diagnostics Inc.	ChLIA	61.1% (0-7 days), 92.9% (7-14 days), 100% (15+ days)	100.00%
MidaSpot COVID-19 Antibody Combo Detection Kit	Nirmidas Biotech, Inc.	RST	76.9% (7-14 days), 100% (15+ days)	100.00%
Simoa Semi-Quantitative SARS-CoV-2 IgG Antibody Test	Quanterix Corporation	paramagnetic microbead-based sandwich ELISA	45.2% (0-7 days), 87.5% (7-14 days), and 100% (15+ days)	99.2%%
RightSign COVID-19 IgG/IgM Rapid Test Cassette	Hangzhou Laihe Biotech Co., Ltd	RST	100% (IgM, 0-6 days), 0% (IgG, 0-6 days); 85.7% (IgM, 7-14 days), 76% (IgG, 7-14 days); 99.25% (IgM, 14+ days), 98.5% (IgG, 14+ days)	99.43%
ACON SARS-CoV-2 IgG/IgM Rapid Test	ACON Laboratories, Inc.	RST	100% (0-7 days), 100% (8-14 days), 100% (15+ days)	95.90%
Innovita 2019-nCoV Ab Test (Colloidal Gold)	Innovita (Tangshan) Biological Technology Co., Ltd.	RST	(For combined IgG/IgM) 95.6% (8-14 days), 100% (15+ days)	98.03%
LYHER Novel Coronavirus (2019-nCoV) IgM/IgG Antibody Combo Test Kit (Colloidal Gold)	Hangzhou Laihe Biotech Co., Ltd	RST	100% (IgM, 0-6 days), 0% (IgG, 0-6 days); 85.7% (IgM, 7-14 days), 76% (IgG, 7-14 days); 99.25% (IgM, 14+ days), 98.5% (IgG, 14+ days)	99.43%
(ARCHITECT and Alinity i systems)	Abbott Laboratories Inc.	Chemiluminescent microparticle immunoassay (CMIA)	43% (3-7 days); 78.9% (8-14 days); 100% (15+ days)	99.60%
Elecsys Anti-SARS-CoV-2 S (semi-quantitative)	Roche	EChLIA	90.6% (0-7 days), 87% (8-14 days), 96.6% (15+days)	100.0%
COVID-SeroKlir, Kantaro Semi-Quantitative SARS-CoV-2 IgG Antibody Kit	Kantaro Biosciences LLC	ELISA	100% (0-7 days), 100% (7-14 days), 98.87% (15+ days)	99.6%
Orawell IgM/IgG Rapid Test	Jiangsu Well Biotech Co., Ltd.	RST	97.1%	100.0%
BIOTIME SARS-CoV-2 IgG/IgM Rapid Qualitative Test	Xiamen Biotime Biotechnology Co., Ltd	RST	IgG: 46.38% (days 0-7), 67.65% (days 7-14), 100% (days 14+); IgM: 55% (days 0-7), 94% (days 7-14), 100% (days 14+)	99.23%%
Access SARS-CoV-2 IgM	Beckman Coulter	ChLIA	91.7%(8-14 days); 98.3%(15+ days)	99.9%
cPass SARS-CoV-2 Neutralization Antibody Detection Kit	GenScript USA, Inc.	Modified ELISA	100.0%	100.0%
Dimension Vista SARS-CoV-2 Total antibody assay (COV2T)	Siemens Healthcare Diagnostics Inc.	ChLIA	91.3% (7-13 days), 100% (15+ days)	99.8%
Dimension EXL SARS-CoV-2 Total antibody assay (CV2T)	Siemens Healthcare Diagnostics Inc.	ChLIA	91.3% (7-13 days), 100% (15+ days)	99.8%
CareStart COVID-19 IgM/IgG	Access Bio, Inc.	RST	96.7% (IgG); 89% (IgM); 98.44% (combined)	99.45% (IgM); 99.45%(IgG); 98.9% (combined)
Platelia SARS-CoV-2 Total Ab assay	Bio-Rad	Modified ELISA	98%	99%
Q-Plex SARS-CoV-2 Human IgG (4 Plex)	Quansys Biosciences, Inc.	ELISA	100% (0-7 days, n=4), 100% (8-14 days, n=13), 95.2% (15+days, n=22)	99.70%
VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG Reagent Pack	Ortho-Clinical Diagnostics, Inc.	ChLIA	83% (12-15 days), 100% (15 days+)
Elecsys Anti-SARS-CoV-2	Roche	EChLIA	From 0-6 days, 65.5%; from 7-13 days, 88.1%; from 14 days onward, 100%	99.81%
LIAISON SARS-CoV-2 S1/S2 IgG	DiaSorin Inc.	ChLIA	90% (8-14 days), 97% (15+ days)	98%
Biohit SARS-CoV-2 IgM/IgG Antibody Test Kit	Biohit Healthcare (Heifei) Co. Ltd.	RST	33% (IgM, days 1-7), 56.6% (IgG days 8-14), 83.% (IgM days 8-14), 96.2% (IgG days 15+), 97.7% (IgM days 15+)	99.46% (IgM), 100% (IgG)
MosaiQ COVID-19 Antibody Magazine	Quotient Suisse SA	solid-phase photometric immunoassay	100.0%	99.8%
AdviseDx SARS-CoV-2 IgM (ARCHITECT and Alinity i systems)	Abbott Laboratories Inc.	CMIA	95%	99.6%
Maverick SARS-CoV-2 Multi-Antigen Serology Panel v2	Genalyte, Inc	photonic ring immunoassay (PRI)	66.7% (0-7 days); 90.91% (8-14 days); 96.1% (15+ days)	97.7%%
ZEUS ELISA SARS-CoV-2 IgG Test System	ZEUS Scientific, Inc.	ELISA	100%	99.1%
OmniPATH COVID-19 Total Antibody ELISA Test	Thermo Fisher Scientific	ELISA	19% (0-7 days), 76.7% (8-14 days), 100% (15+days)	100%
Nirmidas COVID-19 (SARS-CoV-2) IgM/IgG Antibody Detection Kit	Nirmidas Biotech, Inc.	RST	IgM: 97.1% IgG: 100%	94.80%
FREND COVID-19 total Ab	NanoEntek America, Inc.	immunofluorescence assay	100.0%	100.0%
DiaSorin LIAISON SARS-CoV-2 IgM Assay	DiaSorin, Inc.	ChLIA	92.60%	99.3%
Assure COVID-19 IgG/IgM Rapid Test Device	Assure Biotech (Hangzhou Co, Ltd.)	RST	95%	100%
SARS-CoV-2 IgG (ARCHITECT and Alinity i)	Abbott Laboratories Inc.	Chemiluminescent microparticle immunoassay (CMIA)	0% (0-3 days), 25% (3-7 days), 86.4% (8-13 days), and 100% (14+ days)	99.63%
MAGLUMI 2019-nCoV IgM/IgG	Shenzhen New Industries Biomedical Engineering Co., Ltd. (SNIBE)	ChLIA	43.8% (0-7 days), 93.4% (8-14 days), 100% (15+ days)	98.67%
BioCheck SARS-CoV-2 IgM Antibody Test Kit	BioCheck, Inc.	ChLIA	93.7%(8-14 days), 88.9% (15+ days)	97.2%
BioCheck SARS-CoV-2 IgG Antibody Test Kit	BioCheck, Inc.	ChLIA	100%	100%
SGTi-flex COVID-19 IgG	Sugentech Inc.	RST	41.2% (0-7 days), 91.7% (7-14 days), 98.6% (15+ days)	99.2%
COVID-19 ELISA pan-Ig Antibody Test	University of Arizona Genetics Core for Clinical Services	ELISA	97.5%	99.1%
TBG SARS-CoV-2 IgG / IgM Rapid Test Kit	TBG Biotechnology Corp.	RST	IgG: 96.4% IgM: 87.5%	99.8%
Tell Me Fast Novel Coronavirus (COVID-19) IgG/IgM Antibody Test	Biocan Diagnostics Inc.	RST	IgG: 93.3% IgM: 90%	IgG: 96.2% IgM: 98.7%
BioCheck SARS-CoV-2 IgG and IgM Combo Test	BioCheck, Inc.	ChLIA	100% (0-7 days, IgM); 93.8% (7-14 days, IgM); 88.9% (15+days, IgM); 100% (0-7 days, IgG); 100%(7-14 days, IgG); 100% (15+days, IgG)	97.2% (IgM), 100% (IgG)
Diazyme DZ-Lite SARS-CoV-2 IgM CLIA Kit	Diazyme Laboratories, Inc.	ChLIA	26.1% (0-7 days); 83.3% (7-14 days), 94.4% (15+days)	98.30%
VIDAS SARS-CoV-2 IgM	bioMérieux SA	Enzyme linked fluorescent assay (ELFA)	53.8% (0-7 days), 100% (7-14 days), 100%(15+)	99.4%%
VIDAS SARS-CoV-2 IgG	bioMérieux SA	Enzyme linked fluorescent assay (ELFA)	49% (0-7 days), 100% (7-14 days), 100% (15+days)	99.9%%
WANTAI SARS-CoV-2 Ab ELISA	Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.	ELISA	55.4% (0-7 days), 84.8% (7-14 days), 98.7% (15+ days)	98.6%
Atellica IM SARS-CoV-2 IgG (COV2G)	Siemens Healthcare Diagnostics Inc.	ChLIA	56% (0-6 days), 92%(7-14 days), 100% (14+ days)	99.9%
ADVIA Centaur SARS-CoV-2 IgG (COV2G)	Siemens Healthcare Diagnostics Inc.	ChLIA	53.5% (0-6 days), 93.4% (7-14 days), 100% (14+ days)	99.9%
xMAP SARS-CoV-2 Multi-Antigen IgG Assay	Luminex	Fluorescent microbead-based immunoassay (FMIA)	Serum: 71% (days 0-7), 71.4% (8-14 days), 96.2% (14+ days); Plasma: 100% (0-7 days), 82% (8-14 days), 96.6% (14+ days)	Serum: 100%, Plasma: 99.2%
Rapid COVID-19 IgM/IgG Combo Test Kit	Megna Health, Inc.	RST	IgM: 73.81%, IgG, 73.81, Combined: 90.5%	IgM: 99.7%, IgG:99.3%, Combined: 98.9%
Sienna-Clarity COVIBLOCK COVID-19 IgG/IgM Rapid Test Cassette	Salofa Oy	RST	100% for IgM and IgG	100% for IgM and IgG
WANTAI SARS-CoV-2 Ab Rapid Test	Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.	RST	94.7%	98.9%
Diazyme DZ-Lite SARS-CoV-2 IgG CLIA Kit	Diazyme Laboratories, Inc.	ChLIA	92%	97%
SCoV-2 Detect IgM ELISA	InBios International, Inc.	ELISA	93%	99%
Access SARS-CoV-2 IgG	Beckman Coulter, Inc.	ChLIA	75% (0-7 days), 95.3% (8-14 days), 96.8% (15+ days)	100%
Babson Diagnostics aC19G1	Babson Diagnostics	ChLIA/indirect sandwich immunoassay	66.7% (8-14 days), 100% (15+ days), 100% (asymptomatic)	100%
SARS-CoV-2 RBD IgG test	Emory University	ELISA	73% (days 0-7), 100% (days 8-14), 100% (days 14+)	97.7% (prior to pandemic), 94.4% (PCR negative HCW)
SCoV-2 Detect IgG ELISA	InBios International, Inc.	ELISA	97.8%	98.9%
RightSign COVID-19 IgG/IgM Rapid Test Cassette	Hangzhou Biotest Biotech Co., Ltd	RST	96.3% (8-14 days), 94.9% (15+ days) (IgM); 91.6% (8-14 days), 96.2% (15+ days) (IgG)	98.1% (IgM), 99.52% (IgG)
Vibrant COVID-19 Ab Assay	Vibrant America Clinical Labs	ChLIA	98.1%	98.6%
COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma)	Healgen Scientific LLC	RST	96.7% (IgG),86.7 % (IgM), 96.7% combined	98% (IgG), 99% (IgM), 97% combined
Atellica IM SARS-CoV-2 Total (COV2T)	Siemens Healthcare Diagnostics Inc.	ChLIA	60.7% (0-6 days post PCR positive),97.5% (7-13 days post PCR positive), 100% (14+ days post PCR positive).	99.82%%
ADVIA Centaur SARS-CoV-2 Total (COV2T)	Siemens Healthcare Diagnostics Inc.	ChLIA	65.1% (0-6 days post PCR positive),97.5% (7-13 days post PCR positive), 100% (14+ days post PCR positive).	99.81%%
Anti-SARS-CoV-2 ELISA (IgG)	Euroimmun AG	ELISA	From 0-10 days, 13.9%; from 11-20 days, 61.1%; from 21 days onward, 100%. 90% by NCI validation	100% by NCI validation
New York SARS-CoV Microsphere Immunoassay for Antibody Detection	Wadsworth Center, New York State Department of Health	Microsphere immunoassay	Not stated	93-100%
COVID-19 ELISA IgG Antibody Test	Mount Sinai Laboratory	ELISA
qSARS-CoV-2 IgG/IgM Rapid Test	Cellex Inc.	RST	93.80%	95.60%

Serology Tests for COVID-19 | COVID-19 Testing Toolkit

Serology testing for SARS-CoV-2 continues to be in high demand because it can help to better quantify the total number of cases of COVID-19 to date.

www.centerforhealthsecurity.org